References
- Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S16-22. doi:https://doi.org/10.1093/cid/cir865. PMID:22247441
- Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: Pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18:556-69. doi:https://doi.org/10.1128/CMR.18.3.556-569.2005. PMID:16020690
- Shirazi F, Kontoyiannis DP, Ibrahim AS. Iron starvation induces apoptosis in Rhizopus oryzae in vitro. Virulence. 2015;6:121-6. doi:https://doi.org/10.1080/21505594.2015.1009732. PMID:25830548
- Ibrahim AS, Gebremariam T, Lin L, Luo G, Husseiny MI, Skory CD, Fu Y, French SW, Edwards JE Jr, Spellberg B. The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol. 2010;77:587-604. doi:https://doi.org/10.1111/j.1365-2958.2010.07234.x. PMID:20545847
- Ibrahim AS, Gebermariam T, Fu Y, Lin L, Husseiny MI, French SW, Schwartz J, Skory CD, Edwards JE Jr, Spellberg BJ. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest. 2007;117:2649-57. doi:https://doi.org/10.1172/JCI32338. PMID:17786247
- Spellberg B, Kontoyiannis DP, Fredricks D, Morris MI, Perfect JR, Chin-Hong PV, Ibrahim AS, Brass EP. Risk factors for mortality in patients with mucormycosis. Med Mycol. 2012;50:611-8. doi:https://doi.org/10.3109/13693786.2012.669502. PMID:22435877
- Spellberg B, Ibrahim AS, Chin-Hong PV, Kontoyiannis DP, Morris MI, Perfect JR, Fredricks D, Brass EP. The deferasirox-ambisome therapy for mucormycosis (DEFEAT Mucor) study: A randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2012;67:715-22. doi:https://doi.org/10.1093/jac/dkr375. PMID:21937481
- Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis. 2005;41:634-53. doi:https://doi.org/10.1086/432579. PMID:16080086
- Gebremariam T, Liu M, Luo G, Bruno V, Phan QT, Waring AJ, Edwards JE Jr, Filler SG, Yeaman MR, Ibrahim AS. CotH3 mediates fungal invasion of host cells during mucormycosis. J Clin Invest. 2014;124:237-50. doi:https://doi.org/10.1172/JCI71349. PMID:24355926
- Kontoyiannis DP, Azie N, Franks B, Horn DL. Prospective antifungal therapy (PATH) alliance(®): focus on mucormycosis. Mycoses. 2014;57(4):240-6.
- Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev. 2011;24:411-45. doi:https://doi.org/10.1128/CMR.00056-10. PMID:21482731
- Schulze B, Rambach G, Schwartze VU, Voigt K, Schubert K, Speth C, Jacobsen ID. Ketoacidosis alone does not predispose to mucormycosis by Lichtheimia in a murine pulmonary infection model. Virulence. IN PRESS PMID:28750194
- Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: From bench to bedside. Clin Infect Dis. 2009;48:1743-51. doi:https://doi.org/10.1086/599105. PMID:19435437
- Spellberg B, Ibrahim A, Roilides E, Lewis RE, Lortholary O, Petrikkos G, Kontoyiannis DP, Walsh TJ. Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis. 2012;54(Suppl 1):S73-8. doi:https://doi.org/10.1093/cid/cir885. PMID:22247449